Tag Archives: Grail

What I’m Hearing: Marvel’s Misfires; Warners’ ‘Acme’ Reversal, & SAG’s Holy Grail – Puck

  1. What I’m Hearing: Marvel’s Misfires; Warners’ ‘Acme’ Reversal, & SAG’s Holy Grail Puck
  2. Disabled actors and allies on the SAG-AFTRA strike, artificial intelligence at the 2023 Media Access AP Archive
  3. Justine Bateman Criticizes SAG-AFTRA Deal Over AI: Actors Should Only Ratify If ‘They Don’t Want to Work Anymore’ Yahoo Entertainment
  4. Justine Bateman Slams SAG-AFTRA Tentative Deal’s AI Provisions Hollywood Reporter
  5. SAG-AFTRA Strike Ends: Artificial intelligence may cause problems | FOX 5 News FOX 5 Atlanta
  6. View Full Coverage on Google News

Read original article here

Roche’s BTK inhibitor may have reached ‘holy grail’ of brain penetration in phase 2 MS trial – FierceBiotech

  1. Roche’s BTK inhibitor may have reached ‘holy grail’ of brain penetration in phase 2 MS trial FierceBiotech
  2. Mesenchymal Stem Cell Therapy Shows Cognitive and Biomarker Improvements in Multiple Sclerosis Neurology Live
  3. Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Yahoo Finance
  4. Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data FierceBiotech
  5. Merck presents new Evobrutinib data at ECTRIMS | Merck Merck KGaA
  6. View Full Coverage on Google News

Read original article here

Scientists Unlock Secret of Earth’s Core: ‘We Just Found the Holy Grail’ – Newsweek

  1. Scientists Unlock Secret of Earth’s Core: ‘We Just Found the Holy Grail’ Newsweek
  2. Earth’s solid inner core is ‘surprisingly soft’ thanks to hyperactive atoms jostling around Livescience.com
  3. Earth’s inner core is more like a ball of butter than a solid metal sphere, a new study suggests Business Insider India
  4. Something is Moving in the Earth’s Inner Core, and It May Point to the Elusive Source of Our Planet’s Magnetic Field The Debrief
  5. Even Under Incredible Pressures, Iron Atoms At Earth’s Core Can Shift Places IFLScience
  6. View Full Coverage on Google News

Read original article here

Fusion energy, the ‘holy grail’ of clean power, a step closer to reality

Comment

The Department of Energy plans to announce Tuesday that scientists have been able for the first time to produce a fusion reaction that creates a net energy gain — a major milestone in the decades-long, multibillion dollar quest to develop a technology that provides unlimited, cheap, clean power.

The aim of fusion research is to replicate the nuclear reaction through which energy is created on the sun. It is a “holy grail” of carbon-free power that scientists have been chasing since the 1950s. It is still at least a decade — maybe decades — away from commercial use, but the latest development is likely to be touted by the Biden administration as an affirmation of a massive investment by the government over the years.

Huge amounts of public and private funds have been funneled into the fusion race worldwide, with the aim of ultimately manufacturing fusion machinery that could bring electricity to the grid with no carbon footprint, no radioactive waste and far fewer resources than it takes to harness solar and wind power. Beyond the climate benefits, promoters say it could help bring cheap electricity to impoverished parts of the world.

“To most of us, this was only a matter of time,” said a senior fusion scientist familiar with the work of the National Ignition Facility at the Lawrence Livermore National Laboratory in California, where the discovery was made.

Nuclear fusion power inches closer to reality

The development was first reported by the Financial Times on Sunday. It was confirmed by two people familiar with the research, who spoke on the condition of anonymity to avoid getting ahead of the official announcement. Energy Secretary Jennifer Granholm was slated make the announcement Tuesday at a media event billed as the unveiling of “a major scientific breakthrough.”

The department and the lab declined to comment. A lab official said researchers there are still finalizing their analysis and will not be releasing any official findings before Tuesday.

The science of nuclear fusion relies on smashing two atoms together at incredibly high speeds and transforming the energy from that reaction into electricity that can power homes and offices without emitting carbon into the air or dumping radioactive waste into the environment.

In the decades scientists have been experimenting with fusion reactions, they had not until now been able to create one that produces more energy than it consumes. While the achievement is significant, there are still monumental engineering and scientific challenges ahead.

The Inflation Reduction Act could push climate change tech into the future

Creating the net energy gain required engagement of one of the largest lasers in the world, and the resources needed to recreate the reaction on the scale required to make fusion practical for energy production are immense. More importantly, engineers have yet to develop machinery capable of affordably turning that reaction into electricity that can be practically deployed to the power grid.

Building devices that are large enough to create fusion power at scale, scientists say, would require materials that are extraordinarily difficult to produce. At the same time, the reaction creates neutrons that put a tremendous amount of stress on the equipment creating it, such that it can get destroyed in the process.

And then there is the question of whether the technology could be perfected in time to make a dent in climate change.

Even so, researchers and investors in fusion technology hailed the breakthrough as an important advancement.

“There is going to be great pride that this is something that happened in the United States,” said David Edelman, who leads policy and global affairs at TAE, a large private fusion energy company. “This is a very important milestone on the road toward fusion energy.”

It comes as the Biden administration is prioritizing fusion energy research in its climate and energy agenda. The projects are among the front of the line for the tens of billions of dollars in subsidies and grants authorized through the major climate package Biden signed over the summer, called the Inflation Reduction Act.

Over the past several decades, the United States, Russia and various European nations have allocated billions in government dollars trying to master the science, believing that if they could, it would be a boon for the world.

Read original article here

Illumina Wins Case Against FTC on Grail Acquisition

Illumina said the judge rejected the FTC’s position that the deal would hurt competition in the market for multicancer early-detection tests.

“As we’ve stated from the outset, this transaction is procompetitive, will advance innovation, lower healthcare costs and save lives,” said Charles Dadswell, general counsel of Illumina.

The decision, which the FTC staff can appeal, suggests the agency could face hurdles as it tries to push into newer theories of harm that can result from unchecked merger activity. The FTC alleged Illumina’s purchase of Grail could diminish innovation—a concern that goes beyond antitrust’s traditional focus on price levels and output.

In a statement, FTC Bureau of Competition Director Holly Vedova said the agency’s staff is disappointed with the decision and believes it mounted a strong case. “We are reviewing the opinion and evaluating our options,” Ms. Vedova said.

San Diego-based Illumina, which makes genetic-sequencing products, agreed in 2020 to acquire Grail, which is developing blood tests for early cancer detection. Illumina founded Grail and had spun it off in 2017, retaining a minority ownership stake. The 2020 deal was to acquire the part of Grail that it didn’t already own.

But in 2021, the FTC moved to block the deal, claiming that it would harm competition in an emerging field of tests for early-stage detection of multiple types of cancers.

The FTC said Grail and other developers of early-stage cancer tests all rely on Illumina’s DNA-sequencing platform. “If the acquisition is consummated, Illumina will gain the incentive to foreclose or disadvantage firms that pose a significant competitive threat to Grail,” the FTC wrote in its complaint last year. Illumina countered that it has made an open offer to provide continued access to its DNA sequencing to any Grail competitors.

Illumina closed its acquisition of Grail in 2021, despite the pending legal challenges.

The case isn’t the first time that Chief Administrative Law Judge D.

Michael Chappell

has ruled against the FTC on one of its lawsuits. Earlier this year, he rejected the FTC’s challenge of

Altria Group Inc.’s

purchase of a large stake in e-cigarette maker Juul Labs Inc. The FTC’s staff appealed that decision. The case is now pending before the commissioners.

Judge Chappell also ruled against the FTC in a data-security case in 2015.

The FTC under Chair Lina Khan has investigated more proposed mergers and vowed to take a stronger position against deals that could threaten competition. Ms. Khan has said antitrust enforcers need to be more forward-looking, prioritizing concerns such as preserving incentives for innovation, protecting workers and buttressing small businesses.

Illumina’s deal was an example of vertical merger, a type of transaction that integrates complementary instead of competing companies, allowing the combined firm to expand into new or related businesses or lower its input costs. Vertical deals have often been viewed with far less skepticism, but the FTC last year withdrew guidelines for reviewing them, indicating enforcers planned to apply tougher scrutiny to them.

“This case was always something of a stretch,” said

Stephen Calkins,

a law professor at Wayne State University. “It was a vertical case, which is a challenging area of law, and the law judge conspicuously noted during the oral arguments that there were very high stakes in terms of healthcare innovation.”

Illumina’s legal challenges aren’t over, as the FTC’s staff could appeal Judge Chappell’s decision to the agency’s commission. The commission authorized the legal challenge to the deal in March 2021 on a bipartisan vote. If the commission overruled Judge Chappell, the companies could take their case to a federal appeals court.

The FTC had initially sought a federal court injunction that would have blocked the closing of the acquisition, but it backed off because Illumina and Grail were facing antitrust scrutiny in Europe.

Instead, the FTC proceeded with an administrative complaint over the deal, resulting in a trial before an administrative law judge in August and September of 2021. The new ruling arises from that trial and post-trial briefs filed by Illumina and the FTC.

In July, a European Union court ruled that the EU’s competition regulator has jurisdiction to review the Illumina-Grail deal under European merger regulations. Illumina said it intends to appeal that decision. The European Commission said in July that Illumina’s decision to complete the Grail deal breached European regulations.

Illumina is keeping the Grail business separate from the rest of its business while these legal challenges play out.

For Illumina, full control of Grail would give it a solid position in what analysts estimate could be a $50 billion market for tests that can detect multiple cancers early.

Last year, Grail introduced Galleri, a test designed to detect more than 50 types of cancer. The test is intended for people with elevated risk of cancer, such as adults 50 and older, and as a complement to standard single-cancer screening tests. Galleri costs about $950 per test and generally isn’t covered by insurers.

But Galleri sales to date have been lower than expected, as some health systems have taken a measured approach toward using the test.

“We believe it’s a fantastic test,” Illumina Chief Executive Francis deSouza said in an interview. “We believe that in Illumina’s hands, we can make this test available to more people, more affordably and more quickly than in Grail’s hands.” He added that it could save many lives and healthcare costs.

Illumina shares declined 0.5% to $200.62 Thursday. SVB Securities analysts said in a research note that despite the win, there continues to be regulatory uncertainty around the deal, delaying Illumina’s full integration of Grail and its benefits.

Write to Peter Loftus at peter.loftus@wsj.com and Dave Michaels at dave.michaels@wsj.com

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here

‘Holy grail’ trialled by NHS could save thousands of lives by detecting cancer before symptoms show

A blood test for the over-50s being trialled by the NHS could prevent as many as one in ten cancer deaths in the UK.

The Health Service is conducting a world-first trial of the test, which aims to detect more than 50 types of cancer before symptoms show.

Although there are no results yet, researchers are optimistic that it has ‘enormous’ potential. Based on modelling, they believe the ‘Holy Grail’ test could prevent about 10 per cent of cancer deaths, of which there are around 167,000 in the UK every year – nearly 460 a day.

The breakthrough could save around 16,000 lives annually.

Hundreds taking part in the trial of 140,000 volunteers are already being referred for a scan or colonoscopy as a result of the test’s findings. It is expected around half of those referred could have cancer.

If the trial proves successful, the test will be rolled out to a million more people as early as 2024, then possibly nationwide.

If the test were made available across the UK and offered to around 18million adults aged 50 to 79, roughly 130,000 more people without symptoms would receive cancer screening referrals each year, assuming one in a hundred test positive as investigators expect.

British researchers believe the cancer test – by US company Grail – could be a ‘turning point’ in how the NHS tackles the disease.

Currently there are almost three million urgent cancer referrals annually, based on figures for the year to February, so the test would increase referrals by around 5 per cent.

The researchers point out that many of these referrals would happen anyway, but at a later date.

The NHS is grappling with a post-Covid backlog of cancer referrals, and leaked data this month showed more than 10,000 people are waiting for treatment three months after having been referred for suspected cancer. But it is hoped this situation will have changed by the time the test is potentially rolled out.

Professor Peter Sasieni, one of three lead investigators of the trial from King’s College London, said: ‘The potential of this blood test to dramatically cut the number of people who die from cancer is enormous. Of course, if the test is rolled out by the NHS, we will see some increase in short-term workload from the slightly higher number of referrals for cancer.

‘But in the long run, there should also be many savings for the NHS, such as a reduction in the need for chemotherapy and expensive drugs for advanced cancers.’

The blood test, called the Galleri test, picks up fragments of DNA linked to cancer which are shed into the blood, and can suggest which part of the body it has come from. It revolutionises the way cancer is detected, as most patients are currently diagnosed only after developing symptoms.

Based on modelling, they believe the ‘Holy Grail’ test could prevent about 10 per cent of cancer deaths, of which there are around 167,000 in the UK every year – nearly 460 a day

It will become clear only after the NHS trial results are published whether the test can prevent around 10 per cent of all cancer deaths, as the modelling suggests.

But the test provides hope for hard-to-detect cancers such as ovarian and pancreatic, which are usually picked up far too late.

The NHS trial, led by Cancer Research UK, King’s College London Cancer Prevention Trials Unit and Grail, saw people aged 50 to 77 sent letters of invitation.

Those with a signal of cancer in their blood were referred for a scan within a two-week target, which is expected to apply if the blood test is offered routinely. Researchers are not yet revealing what proportion of those referred to hospital in the NHS trial turned out to have cancer, but previous studies suggest it could be 30 to 70 per cent.

By comparison, less than 10 per cent of people referred to hospital following breast or bowel cancer screening will actually have cancer. Half of people in the NHS trial did not have their blood sample tested. Their rate of advanced cancer will be compared with that of those given the test. If it is significantly higher, that suggests the test has prevented people developing an advanced cancer.

The 130,000 referrals in the UK using the cancer blood test is based on people aged 50 to 79 using it, if 70 per cent of them accepted the invitation.

Early results from the trial will be shared with the NHS in 2024.

Rose Gray, of Cancer Research UK, said: ‘Research like this is crucial for making progress against late-stage cancers, and giving more patients the chance of a good outcome.’

‘This test could prevent suffering like mine’

It took four years for Hollywood star Olivia Williams to learn her symptoms were the result of a very rare pancreatic cancer.

The British actress saw ten doctors across three continents as she worked on various films, but a tumour the size of two matchboxes in her pancreas went undiagnosed.

Now the 54-year-old, who is about to play Camilla Parker Bowles in The Crown, is championing the Galleri test to detect early signs of pancreatic cancer before symptoms show.

Miss Williams, an ambassador for Pancreatic Cancer UK, has recovered from the disease, which is less deadly than the most common type. But she had half her pancreas, spleen and gallbladder removed, and must now take pills to digest food.

The mother-of-two said: ‘I spent four years suspecting something was wrong but not being sure. This test is the end of that, it’s a gift from the gods. It will prevent that second blow so many of us suffer – that not only do you have cancer, but that it has spread.’

<!- - ad: https://mads.dailymail.co.uk/v8/de/sciencetech/none/article/other/mpu_factbox.html?id=mpu_factbox_1 - ->

Advertisement

Read original article here

Man Cured Of HIV In ‘Holy Grail’ Moment For Medical Researchers: Report

A 66-year-old man in California has been cured of HIV after he received a stem cell donation for leukemia from a donor who was naturally resistant to the virus.

The patient is known as the “City of Hope” patient because he refused to be identified after he was cured, Reuters reported. The patient is the fourth known patient to be cured this way.

The patient was diagnosed with the disease in 1988 but managed to control it for more than 30 years with antiretroviral therapy (ART).

Sharon Lewin, president-elect of the International Aids Society, said that the cure was the “holy grail” and that the story gives “continued hope … and inspiration” for those battling the disease.

The report said that scientists believe that the treatment worked to cure the patient because the stem cell donor had a rare biogenetic makeup where they did not have the receptors needed to be infected by HIV.

Doctors said that they have found no signs of HIV in the man after he stopped antiretroviral therapy (ART) more than a year ago.

“He saw many of his friends and loved ones become ill and ultimately succumb to the disease and had experienced some stigma associated with having HIV,” said Jana Dickter, an infectious disease doctor who treated the patient. His success “opens up the opportunity potentially for older patients to undergo this procedure and go into remission from both their blood cancer and HIV.”

A woman in Spain in her 70s, who was diagnosed at 59, also has showed promising signs of potentially beating the virus after she stopped antiretroviral therapy (ART) more than a decade ago.

The woman quickly received antiretroviral drugs for nine months after becoming infected with the disease, as well as other treatments to boost her body’s immune system, The Wall Street Journal reported. Researchers discovered that she has been able to keep the virus under control because her body “has high levels of two types of immune cells that the virus normally suppresses and that probably help control viral replication.”

Steven Deeks, a professor at the University of California, San Francisco who leads research for an HIV cure, said that new advances in medical technology could soon lead to cures for the disease that can be widely distributed.

“There are fancy new gene editing methods emerging that might one day be able to achieve a similar outcome with a shot in the arm,” he said.

Read original article here

Could sea corals be used to treat CANCER? Scientists discover ‘holy grail’ chemical in soft corals

Could sea corals be used to treat CANCER? Scientists discover a ‘holy grail’ anti-cancer chemical in common soft corals off the Florida coast

  • The chemical, called eleutherobin, has been shown to have cytotoxic properties
  • It was first found in a rare coral off the coast of Australia in the 1990s
  • Since then scientists haven’t been able to find it in high enough quantities
  • Now, scientists have found the chemical in common soft corals near Florida

Scientists have taken a huge step forward in the search for a new treatment for cancer, after discovering a ‘holy grail’ natural anti-cancer chemical in common soft corals.

The chemical, called eleutherobin, was previously identified in a rare coral near Australia in the 1990s, but since then scientists have been unable to find it in high enough quantities for use in a lab.

Now, researchers from the University of Utah have discovered the elusive chemical is also produced by common soft corals living off the coast of Florida.

The team now hopes to recreate the soft coral in the laboratory, in the hope of producing the chemical in the large quantities needed for rigorous testing.

One day, the chemical could be used as a new tool to fight cancer, according to the team.

Scientists have taken a huge step forward in the search for a new treatment for cancer, after discovering a ‘holy grail’ natural anti-cancer chemical in common soft corals (pictured)

Eleutherobin is used by soft corals as a defence against predators, with the chemical disrupting the cytoskeleton – a key scaffold in cells.

However, laboratory studies have shown that the compound can also inhibit the growth of cancer cells.

Having grown up in Florida, Dr Paul Scesa, first author of the study, suspected corals in the area might contain the elusive chemical.

Dr Scesa brought small live samples of corals from Florida to the laboratory in Utah, where the real hunt began.

While previous studies have suggested that eleutherobin is made by symbiotic organisms living inside corals, the researchers suspected this wasn’t the case.

‘It didn’t make sense,’ Dr Scesa said. ‘We knew that corals must make eleutherobin.’

Having grown up in Florida, Dr Paul Scesa (pictured), first author of the study, suspected corals in the area might contain the elusive chemical

Dr Scesa brought small live samples of corals from Florida to the laboratory in Utah, where the real hunt began

In the laboratory, the researchers set out to understand whether the coral’s genetic code carried instructions for making the compound.

This proved difficult, as the scientists didn’t know what the instructions for making the chemical should look like.

‘It’s like going into the dark and looking for an answer where you don’t know the question,’ said Professor Eric Schmidt, co-lead author of the study.

To address this issue, the researchers looked for regions of coral DNA that resembled genetic instructions for similar compounds from other species.

They then programmed bacteria grown in the lab to follow coral DNA instructions specific to the soft coral, and found they were able to replicate the first steps for making the chemical.

According to the researchers, this proves that soft corals are the source of eleutherobin.

The team now hopes to fill in the missing steps of the chemical’s recipe, and try to replicate them in the laboratory.

‘My hope is to one day hand these to a doctor,’ Dr Scesa added.

‘I think of it as going from the bottom of the ocean to bench to bedside.’

Coral expel tiny marine algae when sea temperatures rise which causes them to turn white

Corals have a symbiotic relationship with a tiny marine algae called ‘zooxanthellae’ that live inside and nourish them. 

When sea surface temperatures rise, corals expel the colourful algae. The loss of the algae causes them to bleach and turn white. 

This bleached states can last for up to six weeks, and while corals can recover if the temperature drops and the algae return, severely bleached corals die, and become covered by algae. 

In either case, this makes it hard to distinguish between healthy corals and dead corals from satellite images.

This bleaching recently killed up to 80 per cent of corals in some areas of the Great Barrier Reef.

Bleaching events of this nature are happening worldwide four times more frequently than they used to. 

An aerial view of Australia’s Great Barrier Reef. The corals of the Great Barrier Reef have undergone two successive bleaching events, in 2016 and earlier this year, raising experts’ concerns about the capacity for reefs to survive under global-warming



Read original article here

New blood test can spot more than 50 types of cancer – many hard to detect early

The sooner most cancers are discovered, the better the odds they can be successfully treated.

Mayo Clinic participated in research on a test that can detect more than 50 cancers. Doctors call it a game-changer, CBS Minnesota reports.

“My dad, he was a healthy guy. He didn’t have any known risk factors for cancer,” Dr. Julia Feygin said. Feygin lost her 40-year-old father to pancreatic cancer when she was 13. Diagnosed at stage three, he lived for nine more months.

“I strongly believe that purpose can be found in everything that happens,” Feygin said.

She’s now part of a team at a Menlo Park, California-based company called GRAIL that’s introducing the blood test, called Galleri. She says can it catch hard-to-detect, aggressive and often deadly cancers like pancreatic, ovarian and esophageal.

“If cancers can be detected early, we can dramatically improve patient outcomes,” Feygin said.

Feygin explains that our blood contains a DNA signature. The blood test tracks the DNA a cancer cell sheds.

Two tubes of blood are drawn and sent to GRAIL’s lab for analysis.

“We can find and sequence these tiny bits of tumor-derived DNA in the blood and, based on the patterns we see, we can reveal if there is a signal for cancer present. We can predict with very high accuracy where in the body this cancer signal is coming from,” Feygin said.

The results are sent back to the health care provider in 10 business days.

An interventional study that included Mayo Clinic with 6,600 participants returned 29 signals that were followed by a cancer diagnosis.

Another study found a less than 1% false positive rate.

There are some caveats on who can get the test.

“It’s intended to be used for people at an elevated risk for cancer. This can be something as simple as age,” Feygin said.

Right now, the test is by prescription-only. Insurance doesn’t cover it. You would pay out of pocket with a current cost of $949.

“In the year 2021, this is so far beyond anything else we’ve been able to do. This is a game-changer,” said Dr. Greg Plotnikoff.

He has prescribed the test for patients and family members with risk factors, saying cancers caught early are in more treatable stages.

“If we can catch things earlier, we have a chance then to make a significant difference,” Plotnikoff said.

He also chose to screen himself, since he is over 60.

“If there was any kind of signal, I wanted to know it and be able to do something about it,” Plotnikoff said.

The American Cancer Society says 71% of cancer deaths come from types of cancer that have no recommended screening.

Feygin says they hope to change outcomes for families like hers in the future.

“It really presents an unprecedented opportunity to bend the cancer mortality curve and really save so many lives,” Feygin said.

GRAIL says Galleri “is intended to be complementary to, and not a replacement of, U.S. guideline-recommended cancer screening.”

GRAIL is still working on full FDA approval. You can ask your doctor to request the test.

Before the end of the year, Galleri will be available at Mayo Clinic locations in Rochester, Minnesota, Jacksonville, Florida, and Phoenix. It will also be available at Mayo Clinic Health System sites in southern Minnesota and Wisconsin.

Read original article here

A ‘Holy Grail’ of American Folk Art, Hiding in Plain Sight

John Foster was driving through St. Louis in 2019 when he spotted something unusual on the front porch of a home just east of Forest Park.

“I thought, ‘That doesn’t look like just a piece-of-concrete lawn ornament,’” said Foster, a St. Louis-based author, historian and art enthusiast.

He couldn’t stop at the time, but the remarkable carving — a pair of seated stone women, their bodies flecked with moss — stuck in his mind. He returned a few weeks later and knocked on the door.

“Can I take a closer look?” he asked the couple who answered, Sally Bliss and her husband, Jim Connett.

He bent down and examined it. The faces were obscured by the green moss, but the distinctive small mouths resting directly beneath vertical noses, nearly closed eyes, and contrast in surfaces between the flatness of the dress and the fluffiness of the bottom left no doubt: This was the work of the stone carver William Edmondson, the first Black artist to have a solo show at the Museum of Modern Art.

“It was like finding the Holy Grail,” Foster said. “Edmondson worked in Nashville, so who would ever dream that a piece would be in St. Louis?”

Bliss, 84, whose first husband, Anthony A. Bliss, inherited the sculpture from his art collector parents, was thrilled by the discovery. (Anthony Bliss’s father, Cornelius N. Bliss Jr., was the brother of a founder of MoMA, Lillie P. Bliss.) Sally Bliss had known the piece had been carved by an African American sculptor — she thought his name might have been Robertson — but had not been aware of its full significance.

Foster encouraged the couple to place the work in a museum — and since Bliss, a former principal dancer with the Metropolitan Opera and New York City Opera, had lived in New York for more than 50 years, Foster suggested the American Folk Art Museum. He reached out to a friend, Valérie Rousseau, a curator at the museum, who flew to St. Louis to examine it.

Rousseau suspected the 10-inch-tall carving was one of Edmondson’s “Martha and Mary” sculptures, whose whereabouts had been unknown for decades. It had last been displayed at an exhibition at the Jeu de Paume museum in Paris in 1938 called “Three Centuries of American Art.” Then it kind of fell off the map.

Even though it was covered with green moss, Rousseau said, “the details were clear enough — like a notch near the knee — to indicate that it was the same as an image of the piece from the Jeu de Paume 1938 exhibition catalog.”

What had happened, she discovered, was that while the 1938 catalog identified the owner as Mrs. Cornelius N. Bliss Jr. — Sally Bliss’s mother-in-law — when the image had been reprinted in Edmund L. Fuller’s 1973 book “Visions in Stone: The Sculpture of William Edmondson,” it carried a new caption: “Owner Unknown.” (The book, with its first monograph of Edmondson’s work, has become a reference for scholars of the artist.)

“MoMA, which organized the Paris show, provided these images to Fuller without also providing the owner of the piece,” she said. “So there was this gap.”

Though Edmondson had work included in the exhibition in Paris, national and international interest in his art was fleeting. He was the subject of only two solo shows during his lifetime, one at MoMA in 1937, and the other at the Nashville Art Gallery in 1941. He died in 1951 in Nashville after struggling financially during his final years.

Edmondson’s work never fetched large sums while he was alive, and many of the approximately 300 pieces he created over his roughly 15-year career ended up in people’s gardens and backyards — just the kind of outsider art that another artist was drawn to.

Brian Donnelly, known professionally as KAWS, was brought in to assist — he is also a member of the American Folk Art Museum’s board. He thought it was important for the museum to have, and it is a promised gift to the museum from KAWS within the next 20 years. He bought the piece and it was transported to New York. (KAWS and the museum declined to reveal the price.)

Over the summer, it was cleaned and conserved. The sculpture will go on display with other works by Edmondson at the American Folk Art Museum in “Multitudes,” a 60th anniversary exhibition for the museum that begins on Jan. 21, 2022.

“As an admirer of William Edmondson’s work, I’m happy this sculpture will have a home at the American Folk Art Museum,” KAWS said in a statement, “where a wider audience might also discover the importance of this incredible artist.”

A striking aspect of the sculpture, which merges quotidian and biblical themes, is the women’s nearly closed eyes and passive posture of students listening to a teacher, Rousseau said — especially Martha, who’s normally presented as busy, preparing food for the guests at the Last Supper.

“It could be a way to illustrate the excess of our society,” she said. “It may be Edmondson’s take on wealth — why should we ask more when we have enough? The important part is to listen when Jesus is trying to teach us something about life, not to provide an extra big banquet for all the guests who are going to come.”

Edmondson, who was self-taught, was born on a plantation near Nashville, Tenn., to formerly enslaved parents. He began sculpting in 1934, when he was about 60, after he reported seeing a vision from God, who told him to begin work on a tombstone.

He carved grave markers from chunks of discarded limestone from demolished buildings, as well as lawn ornaments, bird baths and decorative sculptures. His work often featured biblical characters — the sisters Martha and Mary were some of his favorites — as well as angels, animals and community leaders. He forged his own chisels from railroad spikes and sold tombstones to neighbors for a few dollars.

He came to the art world’s attention around 1936 when a neighbor, the writer Sidney Mttron Hirsch, came across Edmondson’s vast sculpture collection. A pair of Hirsch’s friends, Alfred and Elizabeth Starr, introduced Edmondson to several of their artist friends, including Louise Dahl-Wolfe, a photographer for Harper’s Bazaar magazine in New York. She brought Edmondson’s work to the attention of Alfred H. Barr Jr., the director of the Museum of Modern Art.

One of Edmondson’s sculptures, “Boxer,” sold for $785,000 at Christie’s in 2016, setting a record not only for work by Edmondson, but any work of outsider art.

So could there be more Edmondsons lurking in the Midwest?

“Over the years, I’ve heard collectors say it’s very possible there could be a garden piece by Edmondson in someone’s yard that’s grown over and covered with weeds and sunk into the ground,” Foster said. “Who knows? I never dreamed one of his works would somehow magically make its way to St. Louis.”

Read original article here

The Ultimate News Site